Cord Blood Improves Motor Function With Cerebral Palsy

This article originally appeared here.
Share this content:
Cord Blood Improves Motor Function With Cerebral Palsy
Cord Blood Improves Motor Function With Cerebral Palsy

WEDNESDAY, Nov. 29, 2017 (HealthDay News) -- Infusion of autologous umbilical cord blood improves whole brain connectivity and motor function in young children with cerebral palsy (CP), according to a study published online Oct. 28 in Stem Cells Translational Medicine.

Jessica M. Sun, M.D., from the Duke University Medical Center in Durham, N.C., and colleagues conducted a Phase II trial of autologous cord blood (ACB) infusion in children with CP to test whether ACB could improve function. Placebo or a single intravenous infusion of 1 to 5 × 107 total nucleated cells per kilogram of ACB was administered to 63 children ages 1 to 6 years with CP at baseline, followed by the alternate infusion one year later. At baseline and at one and two years post-treatment, motor function and magnetic resonance imaging brain connectivity studies were performed.

The researchers observed no difference in mean change in Gross Motor Function Measure-66 (GMFM-66) scores at one year between placebo and treated groups, although a dosing effect was identified. At one year after ACB treatment, there were significantly greater increases in GMFM-66 scores, above those predicted by age and severity, among those who received doses ≥2 × 107/kg. Additionally, there were significant improvements in Peabody Developmental Motor Scales-2 Gross Motor Quotient scores and normalized brain connectivity.

"Results of this study suggest that appropriately dosed ACB infusion improves brain connectivity and gross motor function in young children with CP," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »